RAS靶向癌症治療的現況與未來趨勢|自然評論臨床腫瘤學 --- The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Nature Reviews Clinical Oncology 自然評論臨床腫瘤學 volume  19,  pages 637–655 (2022)Cite this article 637–655 (2022) 引用這篇文章 48k Accesses 136 Citations 143 Altmetric Metrics details Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state. Some of these inhibitors have proven efficacy in patients with KRASG12C-mu

saved by

• Gem Wu